OncoZenge (ONCOZ) Stock Overview
A clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
ONCOZ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
OncoZenge AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 7.57 |
| 52 Week High | SEK 10.28 |
| 52 Week Low | SEK 4.52 |
| Beta | 1.35 |
| 1 Month Change | 14.70% |
| 3 Month Change | 36.15% |
| 1 Year Change | 28.74% |
| 3 Year Change | 28.31% |
| 5 Year Change | -25.42% |
| Change since IPO | -50.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONCOZ | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 8.0% | -4.4% | 1.7% |
| 1Y | 28.7% | -19.1% | 14.1% |
Return vs Industry: ONCOZ exceeded the Swedish Pharmaceuticals industry which returned -19.1% over the past year.
Return vs Market: ONCOZ exceeded the Swedish Market which returned 14.1% over the past year.
Price Volatility
| ONCOZ volatility | |
|---|---|
| ONCOZ Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.7% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: ONCOZ has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: ONCOZ's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 1 | Stian Kildal | oncozenge.com |
OncoZenge AB (publ), is a clinical-stage pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. The company offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was founded in 2020 and is headquartered in Bromma, Sweden.
OncoZenge AB (publ) Fundamentals Summary
| ONCOZ fundamental statistics | |
|---|---|
| Market cap | SEK 117.44m |
| Earnings (TTM) | -SEK 23.12m |
| Revenue (TTM) | SEK 71.00k |
Is ONCOZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCOZ income statement (TTM) | |
|---|---|
| Revenue | SEK 71.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 71.00k |
| Other Expenses | SEK 23.19m |
| Earnings | -SEK 23.12m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Sep 03, 2026
| Earnings per share (EPS) | -1.65 |
| Gross Margin | 100.00% |
| Net Profit Margin | -32,557.75% |
| Debt/Equity Ratio | 2,095.0% |
How did ONCOZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 19:48 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OncoZenge AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fredrik Thor | Redeye |
| Kevin Sule | Redeye |
| Johan Unnerus | Redeye |